Security key
107924102
BridgeBio Oncology Therapeutics, Inc. - Common Stock (BBOT)
CUSIP: 107924102
Q1 2026 13F Holders as of 31 Mar 2026
- Security type / class
- Equity / Common Stock
- Total 13F shares
- 57,435,188
- Total 13F value
- $513,833,746
- Share change
- -541,057
- SEC-reported price per share
- $8.95
- Number of holders
- 67
- Value change
- -$6,100,446
- Number of buys
- 39
- Number of sells
- 17
- Shares outstanding
- 80,101,228
Holder snapshot
6 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q1 2026
Institutions
67
Top holders
10
BBOT full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q2 2026
Previous quarter: Q4 2025
BridgeBio Oncology Therapeutics, Inc. SEC filings
BridgeBio Oncology Therapeutics, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 107924102
Recent filing periods:
Ownership snapshot
Top reported holders of BBOT - BridgeBio Oncology Therapeutics, Inc. - Common Stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Helix Holdings II LLC
Disclosed value leader
Cormorant Asset Managemen...
Comparable rows
15/15
Latest evidence
31 Dec 2025
13D/G
3/4/5
13F
Lead comparable stake: 23%
13D/G row: Helix Holdings II LLC
Showing 1-6 of 15 holder rows.
Quick read
Helix Holdings II LLC leads the comparable SEC ownership view at 23%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Helix Holdings II LLC's linked filing trail.
Comparable ownership
Top 5
Helix Holdings II LLC
23%
BridgeBio Pharma LLC
18%
BlackRock Portfolio Management LLC
7.9%
James E. Flynn
6.2%
BC Global Opportunities IX LP
5.5%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Helix Holdings II LLC |
13D/G
3/4/5
Bihua Chen · Director, 10%+ Owner
|
23%
|
—
17,878,594 shares
|
$0 | 11 Aug 2025 |
| BridgeBio Pharma LLC |
3/4/5
13D/G
10%+ Owner
|
18%
from 13D/G
|
$156,363,757
14,589,846 shares
|
— | 10 Oct 2025 |
| BlackRock Portfolio Management LLC |
13D/G
|
7.9%
|
—
1,498,865 shares
|
$0 | 31 Mar 2025 |
| James E. Flynn |
13D/G
Deerfield Management Company, L.P.
|
6.2%
|
—
4,885,446 shares
|
$0 | 11 Aug 2025 |
| BC Global Opportunities IX LP |
13D/G
|
5.5%
|
$42,740,663
4,365,747 shares
|
$0 | 04 Sep 2025 |
| Sculptor Capital LP |
13D/G
|
5.1%
|
$10,419,544
967,460 shares
|
$0 | 17 Jul 2025 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q1 2026
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
67
Shares
57,435,188
Rows available
67
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q1 2026 vs Q4 2025 Across Filers
Q4 2025 holders
52
Q1 2026 holders
67
Holder diff
15
| Investor | Q4 2025 Shares | Q1 2026 Shares | Share Diff | Share Chg % | Q4 2025 value | Q1 2026 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend